Medline (NASDAQ:MDLN) Given New $53.00 Price Target at JPMorgan Chase & Co.

Medline (NASDAQ:MDLN) had its price objective increased by JPMorgan Chase & Co. from $50.00 to $53.00 in a research note published on Tuesday morning,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

Several other brokerages have also recently weighed in on MDLN. BTIG Research restated a “buy” rating and set a $55.00 target price on shares of Medline in a report on Monday. Sanford C. Bernstein initiated coverage on Medline in a report on Monday, January 12th. They issued an “outperform” rating and a $49.00 price target for the company. Wall Street Zen raised Medline to a “hold” rating in a research note on Saturday, January 10th. Truist Financial assumed coverage on Medline in a report on Monday, January 12th. They issued a “buy” rating and a $52.00 target price for the company. Finally, Stifel Nicolaus set a $55.00 target price on Medline in a research note on Wednesday, February 25th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, Medline has an average rating of “Moderate Buy” and an average target price of $50.62.

Medline Trading Down 1.2%

NASDAQ MDLN opened at $42.88 on Tuesday. The firm has a 50 day moving average price of $44.61. Medline has a 1-year low of $34.89 and a 1-year high of $50.88.

Medline (NASDAQ:MDLN) last announced its quarterly earnings data on Wednesday, February 25th. The company reported ($0.01) earnings per share for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.25). The business had revenue of $7.79 billion during the quarter, compared to the consensus estimate of $7.52 billion. The business’s revenue for the quarter was up 14.8% on a year-over-year basis.

Insider Buying and Selling

In other Medline news, major shareholder Hellman & Friedman Capital Par sold 6,088,371 shares of the firm’s stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $28.37, for a total transaction of $172,727,085.27. Following the completion of the sale, the insider owned 4,806,160 shares of the company’s stock, valued at $136,350,759.20. This trade represents a 55.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Andrew J. Mills bought 2,586,206 shares of Medline stock in a transaction on Thursday, December 18th. The stock was acquired at an average price of $29.00 per share, for a total transaction of $74,999,974.00. Following the transaction, the director directly owned 2,586,206 shares of the company’s stock, valued at approximately $74,999,974. This trade represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Sound Income Strategies LLC purchased a new position in shares of Medline during the 4th quarter worth approximately $25,000. Entrust Financial LLC purchased a new stake in shares of Medline in the 4th quarter valued at $26,000. NBC Securities Inc. acquired a new position in Medline during the 4th quarter worth about $28,000. Global Retirement Partners LLC acquired a new position in Medline during the 4th quarter worth about $31,000. Finally, North Star Investment Management Corp. acquired a new stake in shares of Medline during the fourth quarter worth about $36,000.

Key Medline News

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Multiple analysts raised targets / reiterated buys, increasing upside assumptions for the stock — JPMorgan raised its target to $53 and put an Overweight rating on MDLN. JPMorgan price target raise
• Positive Sentiment: Tigress Financial boosted its target to $60 with a Buy rating, suggesting more upside from current levels. Tigress target raise
• Positive Sentiment: BTIG reaffirmed its Buy rating and $55 target, adding to the cluster of bullish analyst views supporting longer-term demand. BTIG reaffirmation
• Neutral Sentiment: Q4 results were mixed: revenue beat expectations ($7.79B vs. $7.52B and +14.8% y/y) but EPS missed consensus (reported ($0.01) vs. $0.24 est.). Revenue strength supports the growth story, while the EPS miss may raise short-term concerns about margins or one-time items. Q4 results
• Neutral Sentiment: Corporate PR: Medline recognized top distribution centers and safety programs — positive for operations/branding but unlikely to move the stock materially. Distribution center awards
• Negative Sentiment: Large secondary offering closed: 86.25M Class A shares sold at $41.00 by selling stockholders (affiliates of Blackstone, Carlyle, Hellman & Friedman and ADIA); the underwriters exercised the full option for an additional 11.25M shares. Medline itself did not sell shares and received no proceeds — the sizable increase in float and major shareholder sell-downs likely pressured the stock today. Secondary offering close

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.